Mesoblast (US:MESO) Globenewswire·2026-01-28 23:54Core Insights - Mesoblast Limited reported strong sales for Ryoncil® and established a new non-dilutive financing facility, enhancing flexibility for strategic partnerships and label expansion efforts [2][5]. Financial Highlights for the Quarter Ended December 31, 2025 - Ryoncil® gross sales reached US$35 million, marking a 60% increase from the previous quarter [5]. - Net revenues for the quarter were US$30 million [5]. - The company secured a non-dilutive credit line of US$125 million at a fixed interest rate of 8.00% per annum, significantly reducing current debt costs [5]. - Cash reserves stood at US$130 million as of December 31, 2025, with a net operating cash spend of US$16 million for the quarter [5]. Operational Highlights for the Quarter Ended December 31, 2025 - Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients [5][8]. - Early outcomes from the first 25 patients treated with Ryoncil® showed an 84% survival rate after completing the initial 28-day treatment regimen [5]. - A pivotal trial for Ryoncil® in adults is set to begin, targeting a population three times larger than the pediatric group [5]. - Positive feedback was received from the FDA regarding a potential Biologics License Application (BLA) for rexlemestrocel-L in chronic discogenic low back pain, with ongoing Phase 3 trials actively recruiting [5]. Company Overview - Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing proprietary mesenchymal lineage cell therapy technology [7][9]. - The company is focused on expanding its product pipeline, including therapies for heart failure and chronic low back pain [9].